Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK1320 MS in Degenerative Spondylolisthesis and Spinal Stenosis
NCT04483297Phase 1Terminated
- Sponsor
- Asahi Kasei Corporation
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised trial of AK1320 in degenerative spondylolisthesis (DS) and spinal stenosis (2 arms), sponsored by Asahi Kasei Corporation. Primary endpoints: Incidence of Treatment Emergent Adverse Events and Serious Adverse Events at 24 months and Summary of Neurological Status at 24 months. Started Nov 2020; status: terminated.
02
Drugs
AK1320
03
Conditions
degenerative spondylolisthesis (DS)spinal stenosis
Beyond the preview
Go deeper on NCT04483297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483297.